Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedApr 12, 2023Ropinirole 2mg tabletscGMP DeviationsRemedyRepack Inc. · D-0499-2023Class IITerminatedApr 12, 2023Atorvastatin 20 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0498-2023Class IITerminatedApr 12, 2023Tadalafil 5 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0497-2023Class IITerminatedApr 12, 2023Simvastatin 10 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0496-2023Class IITerminatedApr 12, 2023Rosuvastatin 5mg tabletscGMP DeviationsRemedyRepack Inc. · D-0495-2023Class IITerminatedApr 12, 2023Ropinirole 0.5 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0494-2023Class IITerminatedApr 12, 2023Glimepiride 2 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0493-2023Class IITerminatedApr 12, 2023Doxazosin 2 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0492-2023Class IITerminatedApr 12, 2023Atorvastatin 10 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0491-2023Class IITerminatedApr 12, 2023Aripiprazole 5mg tabletscGMP DeviationsRemedyRepack Inc. · D-0490-2023Class IITerminatedApr 12, 2023Testosterone Cypionate InjectioncGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.Azurity Pharmaceuticals, Inc. · D-0489-2023Class IIOngoingApr 5, 2023Dabigatran Etexilate 150mg CapsulesCGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.Ascend Laboratories, LLC · D-0534-2023Class IIOngoingApr 5, 2023Dabigatran Etexilate CapsulesCGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.Ascend Laboratories, LLC · D-0533-2023Class IIOngoingApr 5, 2023Fentanyl 500mcgLack of assurance of sterility: Suspected microbial growth present on external label packaging.Apollo Care · D-0487-2023Class IITerminatedApr 5, 2023SimvastatincGMP deviationsDirect Rx · D-0486-2023Class IITerminatedApr 5, 2023SimvastatincGMP deviationsDirect Rx · D-0485-2023Class IITerminatedApr 5, 2023SimvastatincGMP deviationsDirect Rx · D-0484-2023Class IITerminatedApr 5, 2023SimvastatincGMP deviationsDirect Rx · D-0483-2023Class IITerminatedApr 5, 2023GlimepiridecGMP deviationsDirect Rx · D-0482-2023Class IITerminatedApr 5, 2023GlimepiridecGMP deviationsDirect Rx · D-0481-2023Class IITerminatedApr 5, 2023GlimepiridecGMP deviationsDirect Rx · D-0480-2023Class IITerminatedApr 5, 2023RopinirolecGMP deviationsDirect Rx · D-0479-2023Class IITerminatedApr 5, 2023RopinirolecGMP deviationsDirect Rx · D-0478-2023Class IITerminatedApr 5, 2023FinasteridecGMP deviationsDirect Rx · D-0477-2023Class IITerminatedApr 5, 2023Montelukast Sodium TabletscGMP deviationsDirect Rx · D-0476-2023Class IITerminatedApr 5, 2023Calcitonin Salmon Nasal SprayFailed Impurities/Degradation Specifications and Subpotent Drug: High Out of Specification results for a known and unknown impurity as well as low Out of Specification...Endo Pharmaceuticals, Inc. · D-0475-2023Class IOngoingMar 29, 2023Delsam Pharma's Artificial Eye OintmentNon-Sterility: FDA analysis found unopened tubes to be contaminated with bacteria.Global Pharma Healthcare Private Limited · D-0488-2023Class IIITerminatedMar 29, 2023Dofetilide CapsulesFailed Content Uniformity SpecificationsSun Pharmaceutical Industries Inc · D-0474-2023Class IIOngoingMar 29, 2023DaytranaDefective Delivery System: Out of specification for shear.Noven Pharmaceuticals Inc · D-0473-2023Class IIOngoingMar 29, 2023DaytranaDefective Delivery System: Out of specification for shear.Noven Pharmaceuticals Inc · D-0472-2023Class IIOngoingMar 29, 2023DaytranaDefective Delivery System: Out of specification for shear.Noven Pharmaceuticals Inc · D-0471-2023Class IIOngoingMar 29, 2023DaytranaDefective Delivery System: Out of specification for shear.Noven Pharmaceuticals Inc · D-0470-2023Class IITerminatedMar 29, 2023JARDIANCELabeling: Label Mix-upBoehringer Ingelheim Pharmaceuticals, Inc. · D-0468-2023Class IITerminatedMar 22, 2023Clear EyesFailed Impurities Specification: Out-of-specification (OOS) stability test result was obtained for unspecified impurity.Teva Pharmaceuticals USA Inc · D-0469-2023Class IIITerminatedMar 22, 2023Colchicine TabletsFailed Impurities/Degradation Specifications: An out-of-specification (OOS) result was observed during release testing of one lot for a related substance, i.e...Zydus Pharmaceuticals (USA) Inc · D-0467-2023Class IIITerminatedMar 22, 2023Buprenorphine Transdermal SystemFailed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability...AVEVA Drug Delivery Systems, Inc. · D-0466-2023Class IIITerminatedMar 22, 2023Buprenorphine Transdermal SystemFailed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability...AVEVA Drug Delivery Systems, Inc. · D-0465-2023Class IIIOngoingMar 22, 2023EvamistFailed Content Uniformity Specifications: The Spray Content Uniformity (SCU) requirement for Standard Deviation did not meet the requirement at the 18-month stability...Padagis US LLC · D-0464-2023Class IITerminatedMar 22, 2023Clobazam TabletsCGMP Deviations: Potential risk of Cross ContaminationBreckenridge Pharmaceutical, Inc · D-0463-2023Class IITerminatedMar 22, 2023Clobazam TabletsCGMP Deviations: Potential risk of Cross ContaminationBreckenridge Pharmaceutical, Inc · D-0462-2023